New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Jaime Rubio-Perez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, NY, USA; Department of Medical Oncology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Acrylamides, Aniline Compounds. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: EGFR-mutated non-small cell lung cancer (EGFRmut NSCLC) represents a heterogeneous group of tumors with varying clinical outcomes. Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is inevitable, with emerging evidence suggesting that concurrent genomic alterations influence treatment efficacy. MATERIALS AND METHODS: This retrospective study analyzed 58 stage IV EGFRmut NSCLC patients treated with osimertinib across four hospitals in Madrid, Spain, between March 2021 and February 2023. Comprehensive genomic profiling was conducted using next-generation sequencing (NGS) to evaluate co-mutations. Kaplan-Meier survival curves and Cox regression were applied to assess progression-free survival (PFS) and overall survival (OS). RESULTS: A second co-mutation was identified in 44.1 % of patients, with TP53 (70 %) being the most frequent, followed by EGFR (11.5 %), PI3K (11.5 %), and MET amplifications (7.7 %). Patients with co-mutations exhibited significantly worse PFS compared to those with only EGFR mutations (HR: 8.0, 95 % CI: 1.81-35.4; p = 0.001). Specifically, TP53 co-mutations were associated with reduced PFS (HR: 21.6, 95 % CI: 2.77-169; p < 0.001) and a non-statistically significant trend toward worse OS (HR: 3.10, 95 % CI: 0.89-10.8; p = 0.062). DISCUSSION: This study highlights the prognostic impact of co-mutations, particularly TP53, in EGFRmut NSCLC treated with osimertinib. These findings underscore the need for novel therapeutic approaches and personalized treatment strategies, especially in subgroups with poor prognoses. Trials such as MARIPOSA and FLAURA-2 provide promising evidence for treatment intensification, but careful patient stratification is essential to balance efficacy and toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, NY, USA; Department of Medical Oncology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain. Electronic address: jrubioperez05@gmail.com.
- Department of Medical Oncology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
- Department of Medical Oncology, Institut Gustave Roussy, Paris, France.
- Department of Medical Oncology, Hospital Universitario Fundación de Alcorcón, Spain.
- Department of Pathology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM). Madrid, Spain.
Zitieren
APA
Rubio-Perez, J., Hernandez, R., Santolaya, C., Martin-Soberon, M. C., Zazo, S., Carvajal, N., & Rojo, F. (2025). New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100945
Vancouver
Rubio-Perez J, Hernandez R, Santolaya C, Martin-Soberon MC, Zazo S, Carvajal N, et al. New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100945
BibTeX
@article{RubioPerez2025,
author = {Rubio-Perez, Jaime and Hernandez, Roberto and Santolaya, Carlota and Martin-Soberon, Maria Cruz and Zazo, Sandra and Carvajal, Nerea and Rojo, Federico},
title = {New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100945}
}
EUVIMED